Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 24909173)


IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.

Sun X, Mao Y, Wang J, Zu L, Hao M, Cheng G, Qu Q, Cui D, Keller ET, Chen X, Shen K, Wang J.

Oncogene. 2014 Jun 9. doi: 10.1038/onc.2014.158. Epub 2014 Jun 9. Retraction in: Oncogene. 2014 Aug 28;33(35):4450.


Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.

Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP.

Cancer Biol Ther. 2011 Nov 15;12(10):924-38. doi: 10.4161/cbt.12.10.17780. Epub 2011 Nov 15.


Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.


Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.

Soon PS, Kim E, Pon CK, Gill AJ, Moore K, Spillane AJ, Benn DE, Baxter RC.

Endocr Relat Cancer. 2013 Jan 7;20(1):1-12. doi: 10.1530/ERC-12-0227. Print 2013 Feb.


Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity.

Shekhar MP, Santner S, Carolin KA, Tait L.

Am J Pathol. 2007 May;170(5):1546-60.


Cancer-associated fibroblasts promote proliferation of endometrial cancer cells.

Subramaniam KS, Tham ST, Mohamed Z, Woo YL, Mat Adenan NA, Chung I.

PLoS One. 2013 Jul 26;8(7):e68923. doi: 10.1371/journal.pone.0068923. Print 2013.


GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts.

Luo H, Yang G, Yu T, Luo S, Wu C, Sun Y, Liu M, Tu G.

Endocr Relat Cancer. 2014 Mar 7;21(2):355-69. doi: 10.1530/ERC-13-0237. Print 2014 Apr.


Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.

Khanal P, Yun HJ, Lim SC, Ahn SG, Yoon HE, Kang KW, Hong R, Choi HS.

Oncogene. 2012 Aug 23;31(34):3845-56. doi: 10.1038/onc.2011.548. Epub 2011 Dec 12.


The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.

Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, Joffé EB, Simian M.

Breast Cancer Res Treat. 2012 Jun;133(2):459-71. doi: 10.1007/s10549-011-1766-x. Epub 2011 Sep 21.


Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.


Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts.

Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J.

Neoplasia. 2013 Apr;15(4):409-20.


GRP78 secreted by tumor cells stimulates differentiation of bone marrow mesenchymal stem cells to cancer-associated fibroblasts.

Peng Y, Li Z, Li Z.

Biochem Biophys Res Commun. 2013 Nov 1;440(4):558-63. doi: 10.1016/j.bbrc.2013.09.108. Epub 2013 Oct 7.


Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.

Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.


Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.

Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC.

Cancer Biol Ther. 2011 Jun 1;11(11):938-46. Epub 2011 Jun 1.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk